Acadia Pharmaceuticals Inc. (ACAD)

$21.41

-0.88

(-3.95%)▲

Market is closed - opens 8 PM, 07 Dec 2023

Insights on Acadia Pharmaceuticals Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 118.46M → 211.69M (in $), with an average increase of 25.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 1.11M → -65.17M (in $), with an average decrease of 5950.6% per quarter

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 83.0% return, outperforming this stock by 33.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 20.4% return, outperforming this stock by 79.3%

Performance

  • $21.20
    $22.56
    $21.41
    downward going graph

    0.98%

    Downside

    Day's Volatility :6.03%

    Upside

    5.1%

    downward going graph
  • $14.45
    $33.99
    $21.41
    downward going graph

    32.51%

    Downside

    52 Weeks Volatility :57.49%

    Upside

    37.01%

    downward going graph

Returns

PeriodAcadia Pharmaceuticals Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-17.78%
0.3%
0.0%
6 Months
-7.09%
1.7%
0.0%
1 Year
49.6%
-4.0%
-2.4%
3 Years
-58.24%
17.2%
-6.5%

Highlights

Market Capitalization
3.7B
Book Value
$2.21
Dividend Share
0.0
Dividend Yield
5.43%
Earnings Per Share (EPS)
-0.91
PEG Ratio
-0.42
Wall Street Target Price
32.75
Profit Margin
-23.55%
Operating Margin TTM
-27.29%
Return On Assets TTM
-15.63%
Return On Equity TTM
-37.78%
Revenue TTM
631.9M
Revenue Per Share TTM
3.87
Quarterly Revenue Growth YOY
62.0%
Gross Profit TTM
145.5M
EBITDA
-150.0M
Diluted Eps TTM
-0.91
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.34
EPS Estimate Next Year
0.91
EPS Estimate Current Quarter
-0.43
EPS Estimate Next Quarter
0.24

Analyst Recommendation

Buy
    62%Buy
    33%Hold
    4%Sell
Based on 24 Wall street analysts offering stock ratings for Acadia Pharmaceuticals Inc.(by analysts ranked 0 to 5 stars)
Based on 24 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
13
13
Hold
8
9
10
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 52.97%

Current $21.41
Target $32.75

Company Financials

FY17Y/Y Change
Revenue
124.9M
↑ 620.68%
Net Income
-289.4M
↑ 6.64%
Net Profit Margin
-231.71%
↑ 1334.23%
FY18Y/Y Change
Revenue
223.8M
↑ 79.19%
Net Income
-245.2M
↓ 15.28%
Net Profit Margin
-109.56%
↑ 122.15%
FY19Y/Y Change
Revenue
339.1M
↑ 51.5%
Net Income
-235.3M
↓ 4.05%
Net Profit Margin
-69.38%
↑ 40.18%
FY20Y/Y Change
Revenue
441.8M
↑ 30.28%
Net Income
-281.6M
↑ 19.69%
Net Profit Margin
-63.74%
↑ 5.64%
FY21Y/Y Change
Revenue
484.1M
↑ 9.6%
Net Income
-167.9M
↓ 40.38%
Net Profit Margin
-34.67%
↑ 29.07%
FY22Y/Y Change
Revenue
517.2M
↑ 6.83%
Net Income
-216.0M
↑ 28.66%
Net Profit Margin
-41.76%
↓ 7.09%
Q2 FY22Q/Q Change
Revenue
134.6M
↑ 16.54%
Net Income
-34.0M
↓ 69.92%
Net Profit Margin
-25.28%
↑ 72.63%
Q3 FY22Q/Q Change
Revenue
130.7M
↓ 2.86%
Net Income
-27.2M
↓ 20.08%
Net Profit Margin
-20.8%
↑ 4.48%
Q4 FY22Q/Q Change
Revenue
136.5M
↑ 4.42%
Net Income
-41.7M
↑ 53.5%
Net Profit Margin
-30.57%
↓ 9.77%
Q1 FY23Q/Q Change
Revenue
118.5M
↓ 13.21%
Net Income
-43.0M
↑ 3.11%
Net Profit Margin
-36.32%
↓ 5.75%
Q2 FY23Q/Q Change
Revenue
165.2M
↑ 39.48%
Net Income
1.1M
↓ 102.59%
Net Profit Margin
0.67%
↑ 36.99%
Q3 FY23Q/Q Change
Revenue
211.7M
↑ 28.12%
Net Income
-65.2M
↓ 5950.63%
Net Profit Margin
-30.79%
↓ 31.46%
FY17Y/Y Change
Total Assets
384.5M
↓ 31.48%
Total Liabilities
49.2M
↑ 15.16%
FY18Y/Y Change
Total Assets
540.2M
↑ 40.49%
Total Liabilities
61.1M
↑ 24.18%
FY19Y/Y Change
Total Assets
783.2M
↑ 44.98%
Total Liabilities
84.0M
↑ 37.51%
FY20Y/Y Change
Total Assets
782.6M
↓ 0.07%
Total Liabilities
155.6M
↑ 85.14%
FY21Y/Y Change
Total Assets
700.1M
↓ 10.54%
Total Liabilities
159.2M
↑ 2.33%
FY22Y/Y Change
Total Assets
587.8M
↓ 16.04%
Total Liabilities
187.4M
↑ 17.69%
Q2 FY22Q/Q Change
Total Assets
612.8M
↓ 1.84%
Total Liabilities
177.9M
↓ 0.86%
Q3 FY22Q/Q Change
Total Assets
602.5M
↓ 1.68%
Total Liabilities
176.8M
↓ 0.63%
Q4 FY22Q/Q Change
Total Assets
587.8M
↓ 2.44%
Total Liabilities
187.4M
↑ 5.99%
Q1 FY23Q/Q Change
Total Assets
655.3M
↑ 11.48%
Total Liabilities
281.0M
↑ 49.97%
Q2 FY23Q/Q Change
Total Assets
642.8M
↓ 1.91%
Total Liabilities
247.0M
↓ 12.12%
Q3 FY23Q/Q Change
Total Assets
632.5M
↓ 1.59%
Total Liabilities
270.4M
↑ 9.47%
FY17Y/Y Change
Operating Cash Flow
-217.9M
↑ 3.54%
Investing Cash Flow
92.5M
↓ 135.31%
Financing Cash Flow
31.2M
↓ 94.16%
FY18Y/Y Change
Operating Cash Flow
-167.5M
↓ 23.13%
Investing Cash Flow
-71.5M
↓ 177.31%
Financing Cash Flow
306.6M
↑ 883.22%
FY19Y/Y Change
Operating Cash Flow
-151.1M
↓ 9.76%
Investing Cash Flow
-165.8M
↑ 131.97%
Financing Cash Flow
371.8M
↑ 21.26%
FY20Y/Y Change
Operating Cash Flow
-136.2M
↓ 9.9%
Investing Cash Flow
192.5M
↓ 216.08%
Financing Cash Flow
81.0M
↓ 78.22%
FY21Y/Y Change
Operating Cash Flow
-125.7M
↓ 7.72%
Investing Cash Flow
-71.1M
↓ 136.93%
Financing Cash Flow
18.2M
↓ 77.58%
FY22Y/Y Change
Operating Cash Flow
-114.0M
↓ 9.25%
Investing Cash Flow
73.2M
↓ 203.01%
Financing Cash Flow
8.2M
↓ 54.86%
Q2 FY22Q/Q Change
Operating Cash Flow
-13.1M
↓ 82.8%
Investing Cash Flow
-55.8M
↓ 142.48%
Financing Cash Flow
3.8M
↑ 55.29%
Q3 FY22Q/Q Change
Operating Cash Flow
-727.0K
↓ 94.46%
Investing Cash Flow
15.4M
↓ 127.67%
Financing Cash Flow
287.0K
↓ 92.51%
Q4 FY22Q/Q Change
Operating Cash Flow
-23.9M
↑ 3181.16%
Investing Cash Flow
-17.7M
↓ 214.94%
Financing Cash Flow
1.6M
↑ 462.37%
Q1 FY23Q/Q Change
Operating Cash Flow
-17.9M
↓ 24.82%
Investing Cash Flow
192.5M
↓ 1184.73%
Financing Cash Flow
1.5M
↓ 9.17%
Q2 FY23Q/Q Change
Operating Cash Flow
8.2M
↓ 145.73%
Investing Cash Flow
-194.3M
↓ 200.92%
Financing Cash Flow
5.5M
↑ 273.67%

Technicals Summary

Sell

Neutral

Buy

Acadia Pharmaceuticals Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.
-7.05%
-7.09%
49.6%
-58.24%
17.87%
Moderna, Inc.
Moderna, Inc.
8.62%
-38.31%
-54.89%
-50.93%
320.86%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.38%
9.73%
9.82%
65.7%
115.07%
Novo Nordisk A/s
Novo Nordisk A/s
-1.43%
23.95%
58.41%
192.13%
336.59%
Seagen, Inc.
Seagen, Inc.
0.74%
10.42%
83.05%
20.41%
247.89%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-8.19%
7.19%
13.58%
55.97%
97.18%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.
NA
NA
-0.42
-0.34
-0.38
-0.16
0.05
2.21
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.72
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
23.18
23.18
1.75
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.18
41.18
4.02
2.67
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.38
26.38
0.5
15.04
0.23
0.14
0.0
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.
Buy
$3.7B
17.87%
NA
-23.55%
Moderna, Inc.
Moderna, Inc.
Buy
$30.4B
320.86%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$88.5B
115.07%
23.18
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$459.0B
336.59%
41.18
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.2B
247.89%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.5B
97.18%
26.38
35.94%

Institutional Holdings

  • Baker Bros Advisors LP

    26.11%

  • Vanguard Group Inc

    8.29%

  • BlackRock Inc

    6.11%

  • RTW INVESTMENTS, LLC

    5.96%

  • EcoR1 Capital, LLC

    3.65%

  • FMR Inc

    3.23%

Corporate Announcements

  • Acadia Pharmaceuticals Inc. Earnings

    Acadia Pharmaceuticals Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies

Organization
Acadia Pharmaceuticals Inc.
Employees
580
CEO
Mr. Stephen R. Davis J.D.
Industry
Health Technology

Discover More

FAQs